Susan G. Kreissman, MD
Department / Division
Pediatrics /
Pediatrics-Hematology/Oncology
Address
DUMC 102382
Durham, NC 27710
Appointment Telephone
919-684-3401
Office Telephone
919-684-3401
Fax Telephone
919-681-7950
- MD, New York University Mount Sinai School of Medicine, 1985
- Pediatrics, Children's Hospital at Harvard (Massachusetts), 1985-1988
- Pediatric Hematology-Oncology, Children's Hospital, Dana Farber Cancer Center (Massachusetts)
Clinical Interests
Pediatric oncology, new therapeutics for neuroblastoma, apheresis, high-dose chemotherapy, clinical trials in childhood cancer
Research Interests
The emphasis of Dr Kreissman's clinical research involves the study of childhood neuroblastoma. Neuroblastoma is the most common extracranial solid tumor of childhood and this disease has a diverse clinical phenotype and prognosis. Dr Kreissman has developed, written, and served as national protocol chairman for 2 clinical trials designed to improve outcome for children with the high risk form of this disease through the Children's Oncology Group (COG). The most recent protocol is " A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma" completed accrual and results are being analyzed. Dr. Kreissman also serves as a member of the Neuroblastoma committees for COG, the COG Voting Body Steering Committee, and is PI for COG studies at Duke as well as the Duke PI for the New Approaches to Neuroblastoma Therapy (NANT) consortium. She is involved in designing and implimenting additional new protocols for the treatment of neuroblastoma.
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Quintiles
Representative Publications
Bensimhon, P; Villablanca, JG; Sender, LS; Matthay, KK; Park, JR; Seeger, R; London, WB; Yap, JS; Kreissman, SG. Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group. Pediatric Blood and Cancer. 2010;54:596-602.
(2010)
Abstract
Cairo, MS; Davenport, V; Bessmertny, O; Goldman, SC; Berg, SL; Kreissman, SG; Laver, J; Shen, V; Secola, R; van de Ven, C; Reaman, GH. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. British Journal of Haematology. 2005;128:49-58.
(2005)
Abstract
Kreissman, SG; Rackoff, W; Lee, M; Breitfeld, PP. High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. Journal of Pediatric Hematology/Oncology. 1997;19:309-312.
(1997)
Abstract
Kreissman, SG. Molecular genetics: toward an understanding of childhood cancer. Seminars in Pediatric Surgery. 1993;2:2-10.
(1993)
Abstract
West, DC; Shamberger, RC; Macklis, RM; Kozakewich, HP; Wayne, AS; Kreissman, SG; Korf, BR; Lavally, B; Grier, HE. Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents. Journal of Clinical Oncology. 1993;11:84-90.
(1993)
Abstract
Kreissman, SG; Gelber, RD; Cohen, HJ; Clavell, LA; Leavitt, P; Sallan, SE. Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia. Cancer. 1992;70:2208-2213.
(1992)
Abstract
